Octarine Bio key facts
as of Oct 2026- Developer of cannabinoids and psilocybin derivatives intended to improve the health and well-being of people.
- Octarine Bio is valued at approximately $30.8M as of Oct 2026 (last reported valuation).
- It has raised $16.8M; the latest was Later Stage VC ($11.0M) in Jan 2026.
- Notable investors include InnoFounder, Denmark's Export and Investment Fund, BioInnovation Institute, Unconventional Ventures, Bruce Linton — 16 tracked in total.
- Status: Privately Held (backing).
Octarine Bio's last reported valuation, Jan 2026. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch Octarine Bio: the Monday email on marks, rounds and moves
Octarine Bio funding rounds
No funding rounds for Octarine Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Octarine Bio
16+Octarine Bio valuation
Octarine Bio's last reported valuation was $30.8 million in Jan 2026. No priced round, secondary trade or fund mark has surfaced since.
Octarine Bio investors
16 investors are on record for Octarine Bio, including InnoFounder, Denmark's Export and Investment Fund, BioInnovation Institute and Unconventional Ventures.
About Octarine Bio
Developer of cannabinoids and psilocybin derivatives intended to improve the health and well-being of people. The company harnesses synthetic biology using its biosynthetic platform to develop a range of natural and novel cannabinoid and psilocybin-derived molecules with improved pharmacokinetic and therapeutic properties, enabling healthcare professionals to treat neurological and psychological disorders.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2018
- Employees
- 27
- Website
- octarinebio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.